SAB Biotherapeutics, Inc.
SABSDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SAB-176 | Phase 2 | Influenza A H1N1 | - | - |
High Dose SAB-142 | Phase 2 | Type 1 Diabetes | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in SAB Biotherapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in SAB Biotherapeutics, Inc.'s (SABS) pipeline across Phase 2. Its lead program is SAB-176 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SAB Biotherapeutics, Inc.'s next FDA catalyst?→
SAB Biotherapeutics, Inc.'s (SABS) next tracked catalyst is a Earnings expected November 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SABS biotech catalysts?→
Add SABS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SAB Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.